Telomere Dysfunction Induces Sirtuin Repression that Drives Telomere-Dependent Disease
View on PubMed → | DOI | Publisher
Plain-language summary
Published 2019 in Cell Metab, this work by Amano H and collaborators tackles a specific question within science-focused NMN/NAD+ research.
Key findings reported by the authors
- Mechanistic study in Cell Metab (2019) on NAD+/sirtuin/longevity biology
- Adds to the foundational literature underlying NMN supplementation rationale
- First author: Amano H
What this means for Malaysian buyers
For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the limited end of the evidence spectrum. Limited-tier evidence (mouse, in-vitro, or single small pilot) is hypothesis-generating only; do not extrapolate dosing or efficacy claims to humans without supporting replication. Findings here are most directly relevant to science decisions. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.